Abstract
Background The safety and efficacy of anticoagulation in the presence of hemorrhagic transformation (HT) in cardioembolic acute ischemic stroke (AIS) remain uncertain.
Methods This retrospective study enrolled patients presenting with cardioembolic AIS within 48 hours at a tertiary stroke center between January 2011 and August 2023. Patients who developed HT during hospitalization and underwent follow-up imaging were included, focusing on those with hemorrhagic infarction or parenchymal hematoma type 1. Primary outcomes were HT exacerbation on follow-up imaging and 3-month modified Rankin Scale (mRS) distribution shift, comparing anticoagulation therapy (AC), antiplatelet therapy (APT), and drug discontinuation (NM). The safety outcome was symptomatic intracerebral hemorrhage (sICH) occurrence.
Results Among 763 patients with HT (mean age 74.6±8.9 years, 48.1% male), AC was associated with a higher incidence of HT exacerbation compared to APT (adjusted OR 0.48, 95% CI 0.29-0.80, p-value =0.005). However, AC demonstrated improved 3-month mRS outcomes versus APT (adjusted OR 0.63, 95% CI 0.43-0.92, p-value =0.017) and NM (adjusted OR 0.38, 95% CI 0.26-0.55, p-value <0.001). sICH occurred in 5% of cases overall, with rates of 1.5%, 2.1%, and 11.7% in the AC, APT, and NM groups, respectively (adjusted OR for NM vs. AC: 3.93, 95% CI 1.18-13.16, p-value =0.026).
Conclusion In cardioembolic AIS patients with HT, excluding those with PH-2, anticoagulation may lead to radiological exacerbation without increasing sICH risk, while potentially improving functional outcomes. These findings suggest that the presence of HT should not necessarily preclude the use of anticoagulation therapy in this patient population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
.No external funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The current study was approved by local institutional review boards at all participating centers, including Chonnam National University Hospital (CNUH-2024-294).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used in this study are available upon reasonable request to corresponding author.
